Pharmaceutical for treating schizophrenia

A technology for schizophrenia and drugs, which is applied in the field of medicine, can solve problems such as unacceptable by patients, incompletely clear pathogenesis, and recurrence of the disease, and achieve relatively stable curative effect, which is conducive to rehabilitation and enhances immune function.

Inactive Publication Date: 2017-05-31
HENAN SHUIJINGTOU CULTURAL MEDIA CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, the pathogenesis of this disease is not fully understood
[0003] People pay more and more attention to the treatment of schizophrenia with the combination of traditional Chinese and western medicine. Long-term use of large doses of western medicine for schizophrenia will inevitably lead to sleep disorders and extrapyramidal side effects, which often lead to unacceptable and unacceptable medication for patients, resulting in relapse

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical for treating schizophrenia
  • Pharmaceutical for treating schizophrenia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] In the embodiment of the present invention, a pharmaceutical composition for treating schizophrenia is composed of the following raw materials in parts by weight: 1 part of omeprazole, 7 parts of aspirin, 3 parts of aminotoluic acid, 11 parts of stearic acid, 14 parts of ginger.

[0019] Aspirin is mixed with deionized water whose mass is 12.8 times that of aspirin to prepare an aspirin solution. Mix and grind omeprazole, aminotoluic acid, and stearic acid, add aspirin solution, and stir at 45° C. for 38 minutes to prepare mixture A. The mixture A was ultrasonically treated at a temperature of 58°C for 18 minutes, with an ultrasonic power of 800W, then added alpinol, and subjected to microwave treatment for 5 minutes, with a microwave power of 1000W, then stirred at a temperature of 67°C until dry, and then granulated. pharmaceutical composition.

Embodiment 2

[0021] In the embodiment of the present invention, a pharmaceutical composition for treating schizophrenia is composed of the following raw materials in parts by weight: 5 parts of omeprazole, 15 parts of aspirin, 7 parts of aminotoluic acid, 19 parts of stearic acid, 22 parts of ginger.

[0022] Aspirin is mixed with deionized water whose mass is 12.8 times that of aspirin to prepare an aspirin solution. Mix and grind omeprazole, aminotoluic acid, and stearic acid, add aspirin solution, and stir at 45° C. for 40 minutes to prepare mixture A. The mixture A was ultrasonically treated at a temperature of 58°C for 18 minutes, with an ultrasonic power of 800W, then added alpinol, and subjected to microwave treatment for 5 minutes, with a microwave power of 1000W, then stirred at a temperature of 67°C until dry, and then granulated. pharmaceutical composition.

Embodiment 3

[0024] In the embodiment of the present invention, a pharmaceutical composition for treating schizophrenia is composed of the following raw materials in parts by weight: 2 parts of omeprazole, 9 parts of aspirin, 4 parts of aminotoluic acid, 13 parts of stearic acid, 16 parts of ginger.

[0025] Aspirin is mixed with deionized water whose mass is 12.8 times that of aspirin to prepare an aspirin solution. Mix and grind omeprazole, aminotoluic acid, and stearic acid, add aspirin solution, and stir at 45° C. for 39 minutes to prepare mixture A. The mixture A was ultrasonically treated at a temperature of 58°C for 18 minutes, with an ultrasonic power of 800W, then added alpinol, and subjected to microwave treatment for 5 minutes, with a microwave power of 1000W, then stirred at a temperature of 67°C until dry, and then granulated. pharmaceutical composition.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pharmaceutical for treating schizophrenia. The pharmaceutical composition is prepared by the following raw materials by weight: 1-5 parts of omeprazole, 7-15 parts of aspirin, 3-7 parts of aminomethylbenzoic acid, 11-19 parts of stearic acid, and 14-22 parts of Alpinetin. The preparation method comprises the following steps: mixing and grinding the omeprazole, the aminomethylbenzoic acid and the stearic acid, adding the aspirin solution, stirring for 38-40 min under 45 DEG C of the temperature, carrying out the ultrasonic treatment for 18 min under 58 DEG C of the temperature, wherein the ultrasonic power is 800 W; adding the Alpinetin, and carrying out the microwave treatment for 5 min, wherein the microwave power is 1000 W; and stirring under 67 DEG C of the temperature until the solution is dried, and pelleting to obtain the pharmaceutical. While the pharmaceutical is used for treating the schizophrenia, the curative effect is good and stable relatively, the drug dosage is less without the toxic and side effect, the long-term curative effect is stable, and the immunity is enhanced. The used raw materials are simple and are easily obtained, the preparation process is simple, the operation is easy, the production cost is low, and the pharmaceutical is suitable for the large-scale promotion.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a medicine for treating schizophrenia. Background technique [0002] Schizophrenia is a group of severe mental illnesses of unknown etiology, mostly in young adults with slow or subacute onset, clinically manifested as a syndrome with various symptoms, involving obstacles in perception, thinking, emotion, and behavior and incoordination of mental activity. Patients generally have clear consciousness and basically normal intelligence, but some patients may experience cognitive impairment during the course of the disease. The course of the disease is generally protracted, showing repeated attacks, aggravation or deterioration, and some patients eventually develop decline and mental disability. Modern antipsychotic drugs, especially classic drugs, have serious side effects, which often lead to the failure of maintenance treatment. Modern medicine believes that schizophrenia is a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/616A61K31/4439A61K31/195A61K31/20A61K31/352A61P25/18
CPCA61K31/616A61K31/195A61K31/20A61K31/352A61K31/4439
Inventor 不公告发明人
Owner HENAN SHUIJINGTOU CULTURAL MEDIA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap